Deep Functional Phenotyping of the ALA Lung Health Cohort
ConditionLung Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age25-35
SponsorJohns Hopkins University
About this trial
The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with:
* the structure of the participants lungs' airways, * the structure of blood vessels in the participants lungs and heart, and * the participants lungs' ability to exchange gases.
Participants will take four different lung function tests to measure lung function, including:
* air movement in the lungs (oscillometry) * lung size (slow vital capacity (SVC) and functional residual capacity (FRC) * gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 25-35 years at the time of the baseline examination
Able to read and understand English or Spanish
Has a social security number
Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination.
Disqualifiers
Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) or high dose inhaled corticosteroid [ICS] or add-on long-acting muscarinic antagonist (LAMA); Medium dose = >250 fluticasone, propionate =100 fluticasone furoate, >200 beclomethasone, >400 budesonide, >220 mometasone). The investigators will accept low-dose ICS/LABA or medium dose ICS.
3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
One asthma hospitalization in the past 12 months
History of any chronic lung disease other than asthma including but not limited to chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
Trial population
Young adults between 25 and 35 years of age at baseline
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Associations with airway-parenchymal dysanapsis
Correlation of adverse modifiable exposures and risk factors with increased airway-parenchymal dysanapsis
Time frame
Baseline2
Associations with vascular parenchymal dysanapsis and cardiac chamber size
Correlation of adverse modifiable exposures and risk factors with increased vascular parenchymal dysanapsis and increased cardiac chamber size
Time frame
Baseline3
Associations with diffusing capacity for carbon monoxide (DLCO)
Correlation of adverse modifiable exposures and risk factors with lower diffusing capacity for carbon monoxide (DLCO)
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Johns Hopkins University
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
American Lung Association
Collaborator
University of Vermont
Collaborator
Source ClinicalTrials.gov